Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?

被引:58
作者
Azzato, E. M. [1 ,2 ]
Greenberg, D. [3 ]
Shah, M. [1 ]
Blows, F. [1 ]
Driver, K. E. [1 ]
Caporaso, N. E. [2 ]
Pharoah, P. D. P. [1 ]
机构
[1] Univ Cambridge, Strangeways Res Lab, Dept Oncol, Cambridge CB1 8RN, England
[2] NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD 20852 USA
[3] Eastern Canc Registrat & Informat Ctr, Unit C, Cambridge CB22 3AD, England
关键词
survival analysis; prevalent cases; left truncation; breast cancer; GERMLINE GENETIC-VARIATION; BREAST-CANCER; DISEASE;
D O I
10.1038/sj.bjc.6605062
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Observational epidemiological studies often include prevalent cases recruited at various times past diagnosis. This left truncation can be dealt with in non-parametric (Kaplan-Meier) and semi-parametric (Cox) time-to-event analyses, theoretically generating an unbiased hazard ratio (HR) when the proportional hazards (PH) assumption holds. However, concern remains that inclusion of prevalent cases in survival analysis results inevitably in HR bias. We used data on three well-established breast cancer prognosticators - clinical stage, histopathological grade and oestrogen receptor (ER) status - from the SEARCH study, a population-based study including 4470 invasive breast cancer cases (incident and prevalent), to evaluate empirically the effectiveness of allowing for left truncation in limiting HR bias. We found that HRs of prognostic factors changed over time and used extended Cox models incorporating time-dependent covariates. When comparing Cox models restricted to subjects ascertained within six months of diagnosis (incident cases) to models based on the full data set allowing for left truncation, we found no difference in parameter estimates (P = 0.90, 0.32 and 0.95, for stage, grade and ER status respectively). Our results show that use of prevalent cases in an observational epidemiological study of breast cancer does not bias the HR in a left truncation Cox survival analysis, provided the PH assumption holds true. British Journal of Cancer (2009) 100, 1806-1811. doi: 10.1038/sj.bjc.6605062 www.bjcancer.com Published online 28 April 2009 (C) 2009 Cancer Research UK
引用
收藏
页码:1806 / 1811
页数:6
相关论文
共 15 条
[1]  
[Anonymous], 1997, J CLIN PATHOL
[2]   Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort [J].
Azzato, Elizabeth M. ;
Driver, Kristy E. ;
Lesueur, Fabienne ;
Shah, Mitul ;
Greenberg, David ;
Easton, Douglas F. ;
Teschendorff, Andrew E. ;
Caldas, Carlos ;
Caporaso, Neil E. ;
Pharoah, Paul D. P. .
BREAST CANCER RESEARCH, 2008, 10 (03)
[3]   Risk factors for the incidence of breast cancer: Do they affect survival from the disease? [J].
Barnett, Gillian C. ;
Shah, Mitul ;
Redman, Karen ;
Easton, Douglas F. ;
Ponder, Bruce A. J. ;
Pharoah, Paul D. P. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (20) :3310-3316
[4]  
Brookmeyer R., 2005, ENCY BIOSTATISTICS
[5]   SURVIVAL ANALYSIS IN NATURAL-HISTORY STUDIES OF DISEASE [J].
CNAAN, A ;
RYAN, L .
STATISTICS IN MEDICINE, 1989, 8 (10) :1255-1268
[6]  
Goode EL, 2002, CANCER RES, V62, P3052
[7]  
GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
[8]   Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer [J].
Harvey, JM ;
Clark, GM ;
Osborne, CK ;
Allred, DC .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1474-1481
[9]  
KEIDING N, 1992, NATO ADV SCI I E-APP, V211, P309
[10]  
Keiding N, 2005, ENCY BIOSTATISTICS